H2 Global Group – Tisková konference v ČTK

Jak bude studie probíhat?

Schválená klinická studie je navržena tak, aby co nejpřesněji zhodnotila bezpečnost a potenciální přínosy inhalace molekulárního vodíku u pacientů s kognitivním deficitem.

Základní parametry studie:

• Start: January 2026

• Doba trvání: 6 months

• Počet účastníků: cca 30 pacientů

• Věkové rozmezí: 50 - 80 let

Průběh studie:

• inhalace molekulárního vodíku po dobu 1 hodina denně,

• 5× týdně po dobu 3 měsíců,

• následované tří­měsíční monitorovací fází 3-month monitoring phase bez aktivní intervence.

Studie bude sledovat:

• bezpečnost inhalace molekulárního vodíku

• změny biochemických ukazatelů,

• impact on cognitive functions,

• and quality of life from the patients’ perspective.

Building on Japanese research and a European patent

This clinical study builds on the work of Professor Shigeo Ohta in Japan, one of the co-founders of H2 Global Group. His research led to the granting of the European patent EP3701956B1, covering the prophylaxis and treatment of dementia using molecular hydrogen.

Thanks to this patent, our development is based on a strong scientific and intellectual-property foundation, which enhances:

• the credibility of the technology,

• our position in the field of innovative therapeutic approaches,

• and the future potential for global application.

Czech innovation with global impact

Approval of the clinical study is an important step towards our goal:
to introduce, in 2026, the world’s first medical device using molecular hydrogen, developed in the Czech Republic.

We then plan to expand it to other EU countries, the USA, and Asia. This milestone:

• strengthens our scientific credibility,

• reinforces our regulatory standing,

• and confirms that Czech know-how can play a role in global medicine, particularly in the field of neurodegenerative diseases such as Alzheimer’s dementia.

We are seeking volunteers for the clinical study

As part of today’s announcement, we are also calling for volunteers who wish to actively participate in the research and contribute to improving future options for the prevention and treatment of dementia.

Who are we looking for?

• individuals aged 50–80,

• in generally good health,

• diagnosed with mild cognitive impairment or mild to moderate dementia,

• ideally from Ostrava and the surrounding area (the study is conducted at University Hospital Ostrava).

How to apply?
Interested participants can apply until 30 November 2025 at:
📧 david.skoloudik@H2medical.com

Our thanks and our vision

This step would not have been possible without the support of our partners, experts, and investors who believe that molecular hydrogen can become a new, safe, and non-invasive tool in combating the devastating effects of dementia.

Thank you to everyone who supports us on this journey and helps us develop Czech innovation with global reach.